Myeloprotection effects of trilaciclib in Chinese patients with extensive stage small cell lung cancer (ES-SCLC) receiving chemotherapy—a real-world study
Yongxing Chen, Chong Meng, Lirong Liu, Kai Liu, Tao Chen, Chen Yang · 2024
Read Myeloprotection effects of trilaciclib in Chinese patients with extensive stage small cell lung cancer (ES-SCLC) receiving chemotherapy—a real-world study by Yongxing Chen, Chong Meng, Lirong Liu, Kai Liu, Tao Chen, Chen Yang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11635219.txt.
Description
Yongxing Chen and co-authors reported in 2024 real-world results for a drug that protects bone marrow during chemotherapy for advanced small cell lung cancer. The drug briefly pauses blood-forming cells so chemotherapy harms them less. Thirty Chinese patients received it alongside standard regimens at one center.
Severe drops in infection-fighting white cells occurred in only about seven percent of patients. Serious blood toxicities were uncommon in the main treatment group but universal in the small group on a harsher regimen. About a fifth of patients needed antibiotics. The authors read the data as supporting the drug's protective effect in everyday practice, while the small numbers call for larger confirmatory studies.
Catalog record
| CREATOR | Yongxing Chen, Chong Meng, Lirong Liu, Kai Liu, Tao Chen, Chen Yang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |